APR 07, 2016 01:30 PM PDT

Introduction to exosomes and other extracellular vesicles the "the bodies molecular internet" for personalized & precision medicine.

2 20 1776

  • Cofounder of the EXO Incubator, Pioneer in exosome nucleic acid technologies
      Rey Magaña, is a serial entrepreneur with over 25 years experience in life sciences. Mr. Magana is currently cofounder of the EXO Incubator, a Life Sciences technology incubator and accelerator. EXO Incubator's mandate is to exploit the power of its Exosome and Extracellular Vesicles platform technology to potentiate precision medicine and address critical areas of unmet medical need. Among the disease areas of interest are oncology, metabolic disease, genetics, immunology and infectious disease. EXOi is launching and commercializing technologies, product and companies via portfolio programs spanning applications in molecular diagnostics, drug delivery and therapeutics.

      Previously, he was part of the team that that pioneered extracellular vesicle and exosome nucleic acid technologies for applications in molecular diagnostics, drug delivery and therapeutic. He cofounded Proxy Life Science Holdings a biotechnology company organized to develop those technologies.

      He also cofounded Perry Scientific a contract research organization specializing in pre-clinical research services supporting early stage pharmaceutical, biopharmaceutical and medical device companies. The company catered to both emerging and established blue chip companies. Rey was responsible for strategy, business development and operations. His key duty was for the development and delivery of custom research services including efficacy, pharmacokinetics and safety studies in areas as diverse as oncology, metabolic diseases, cardiology, dermatology, immunology, drug delivery, cosmetics, nutraceuticals and medical devices.


    A recently discovered communication system used by cells to send messages across the human body promises to revolutionize our understanding of disease and how we treat it. Technologies based on this discovery promise to become important tools for our understanding, monitoring and treatment of some of man's most insidious diseases such as cancer. The key elements comprising this communication system are nano and micron sized vesicles often called exosomes or extracellular vesicles (EVs), which are the carriers of the molecular information.
    Exosomes and EVs are produced by most if not all cell types, under normal conditions and especially in response to disease.  Exosomes and EVs are expelled from affected cells and circulate in various bodily fluids including blood, urine and saliva. Importantly, circulating exosomes share certain molecular structures and components in common with their parental cells, including DNA, RNA and Proteins. Exosomes shuttle this molecularly encoded information between cells and across distances, effectively acting as the body's molecular internet. 
    By gathering exosomes via a simple blood draw, information can be accessed representing distant cells, tissues and organs, including information originating from a multitude of diverse diseases such as cancer, Alzheimer's, arteriosclerosis, arthritis, diabetes, and multiple sclerosis (MS) among many others. Unlike invasive tissue biopsies exosomes can be easily collected and interrogated serially. This dynamic accessibility would allow for screening and early detection of disease, monitoring of progression, drug response, recurrence and resistance. Not merely a blue sky technology, exosome and EVs are contributing to personalized and precision medicine today as research tools and may be available for first clinical applications as early as this year.  
    Learning objectives:
    1) understand the origins of exosomes and EVs  
    2) understand the application of exosomes and EV for disease monitoring.

    Show Resources
    Loading Comments...